EHA21: Study raises BMS' hopes for Reblozyl in less severe d...

Bristol-Myers Squibb has taken another step towards achieving its blockbuster hopes for beta thalassaemia-associated anaemia therapy Reblozyl, after hitting the target in a phase 2 trial in

CHMP backs BMS’ first-in-class anaemia drug Reblozyl

Celgene gets speedy review for thalassaemia drug luspatercep...

It’s shaping up to be a landmark year for the community of patients with rare blood disorder beta thalassaemia.

Celgene files potential blockbuster luspatercept

Celgene and Acceleron Pharma have submitted their blood disorder drug luspatercept for approval with the FDA, setting up what could be a new blockbuster for the soon-to-be acquired Celgene.

Celgene scores at ASH18 with double luspatercept data

A pair of clinical trial wins for Celgene’s luspatercept at the American Society of Haematology (ASH) meeting have set up a filing for the new drug in mid-2019.